Abstract
Background Cystic lesions of the pancreas have continued to present a clinical challenge for the past decades now. The increasing rate of detection, the lack of high-quality data on the natural biology of pancreatic cysts and the resulting difficulty to predict malignant transformation in different types of pancreatic cysts make patients with these diseases hard to manage. The German Pancreas Club Cyst Registry (GERPACYST) (DRKS00025927) establishes a platform to discover the natural entity specific biology of pancreatic cysts, in a multicenter manner that should allow to assess risk models for malignancy.
Method This manuscript is written according to the SPIRIT guidelines. Ethical approval was obtained from the University of Luebeck (2024-265_1). In GERPACYST patients aged ≥18 years with a pancreatic cyst under surveillance or scheduled for surgery should be enrolled. Participating centers will complete an electronic Case Report Form (eCRF) via REDCap which is designed as a longitudinal study minimizing the input of repeated measures. Changes in patient baseline data, cyst characteristics, both endoscopic and imaging data will be entered typically every 6-12 months during patient follow-up. Biobanking will be performed, when available. Duration of observation per patient is up to a maximum of 20 years or until end of follow-up or death.
Discussion GERPACYST will provide a valuable platform for clinical outcomes research. Fundamental factors affecting the development of pancreatic cysts over time will be identified. New research questions might be answered during the study period.
Trial registration The study was prospectively registered at the German Clinical Trial Register (DRKS) under DRKS00025927 on September, 14th, 2021 before inclusion of the first patient. The Universal Trial Number (UTN) is U1111-1302-9822.
Trial sponsor The study is sponsored by the German Pancreas Club (DPC) e.V. The sponsor has no role in study design, collection, management, interpretation or writing of the report. It is a mere supportive sponsoring.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00025927
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the University of Luebeck (2024-265_1).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Parts of the study are currently funded by The Federal Ministry of Education and Research (BMBF) (Funding number: 01KD2412A) and was supported by the Clinician-scientist school Luebeck (project number 413535489) to KCH.
The study protocol has been presented at the annual meeting of the Digestive Disease Week 2024 and the German Society of Visceral Medicine 2023.
There are no conflicts to declare. Data is available from the first author KCH.
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.
List of abbrevations
- IPMN
- (intraductal papillary-mucinous neoplasia)
- MCN
- (mucinous-cystic neoplasia)
- SCA
- (serous cystic adenoma)
- SPN
- (solid pseudopapillary neoplasia) or
- SPPT
- (Solid pseudopapillary tumors)
